RAEB


Also found in: Acronyms.

RAEB

Refractory Anemia with Excess myeloBlasts, see there.
References in periodicals archive ?
The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
of treatment Patients Treatment (day) <5% 0-15% References 37 * HDMP 4-7 12(32%) 20(54%) 58 26 * HDMP+ Ara-c 15 7(27%) 17(61%) 59 4 ** HDMP+LD-Ara-c 4(100%) -- 8 ** HDMP 4 7(88%) 8(100%) 79 * AML, ** RAEB and RAEB-t, Ara-c (3mg/kg, 3 days a week), LD Ara-c (10 mg/[m.sup.2]) HDMP: High-dose methylprednisolone; LD Ara-c: Low-dose cytosine arabinoside; AML: Acute myeloblastic leukemia; MDS: Myelodysplastic syndrome; RAEB: Refractory anemia with excess of blasts; RAEB-t: RAEB in transformation
A total of 41 samples comprising the FAB subtypes RA, RARS, RAEB, RAEB-t and MDS/AML were analysed for promoter hypermethylation of five genes.
In our study E-cadherin promoters were methylated in 39 per cent of the cases and it is predominantly associated with RAEB, RAEB-t and AML patients.
of sub types Number methylated cases Percentage RA 17 p15 7 41.2 p16 4 23.5 MGMT -- -- E-cadherin 3 17.6 RAEB 9 p15 7 77.8 p16 5 55.6 MGMT -- -- E-cadherin 4 44.4 RARS 4 p15 2 50.0 p16 1 25.0 MGMT -- -- E-cadherin 2 50.0 RAEB-t 6 p15 5 83.3 p16 2 33.3 MGMT -- -- E-cadherin 3 50.0 MDS/AML 5 p15 4 80.0 p16 3 60.0 MGMT 2 40.0 E-cadherin 4 80.0 RA, refractory anaemia; RARS, refractory anaemia ringed sideroblast; RAEB, refractory anaemia excess blast; RAEB-t, refractory anaemia excess blast in transformation; AML, acute myelocytic leukaemia
To demonstrate the feasibility and power of this approach, we analyzed the very heterogeneous methylation pattern of the CpG islands of the tumor suppressor gene CDKN2B in bone marrow samples from patients with different MDS subtypes (RA, BARS, and RAEB) and from patients with CMML and AML, and in 32 control samples displaying only mild reactive changes.
In the patient samples, mean (SD) methylation levels were 6% (5%), 6% (6%), 11% (8%), 11% (9%), and 21% (13%), for RA, BARS, RAEB, CMML, and AML, respectively.
Only the comparison of RAEB and CMML did not show significant differences in any region.
(figure 2) Bone marrow examination confirmed the diagnosis of AML in 2 (one of which was AML-M7), RAEB in 1 and aplastic anemia in 2 cases.
Bone Marrow and Blasts 35% Blasts 14% Aplastic anemia Final Diagnosis AML RAEB Features Case IV Case V 1.
Age, y/Sex Final Diagnosis MDS patients 1 72/F RA 2 77/M RA 3 58/M RARS 4 79/M RARS 5 82/M RARS 6 54/M RAEB (8% blasts) 7 83/F MDS, unclassified Control patients 8 64/F Lymphoma without BM involvement 9 48/F Lymphoma without BM involvement 10 63/M Lymphoma without BM involvement 11 67/M Lymphoma without BM involvement 12 62/F Lymphoma without BM involvement 13 65/M Lymphoma without BM involvement 14 72/F Lymphoma without BM involvement Case No.
(*) MDS indicates myelodysplastic syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess of blasts; RAEB-T, RAEB in transformation; AML, acute myelogenous leukemia; BM, bone marrow; NR, not relevant; and ND, not done.